A simple nasal spray of tiny antibodies produced by llamas could provide a new frontline treatment against the coronavirus that causes COVID-19, according to a study.
Researchers at the Rosalind Franklin Institute in the UK found that nanobodies -- a smaller, simple form of antibody -- can effectively target the SARS-CoV-2 virus.
The study, published in the journal Nature Communications, shows that short chains of the molecules, which can be produced in large quantities in the laboratory, significantly reduced signs of the COVID-19 disease when administered to infected animal models.
The nanobodies, which bind tightly to the SARS-CoV-2 virus, neutralising it in cell culture, could provide a cheaper and easier to use alternative to human antibodies taken from patients who have recovered from COVID-19, the researchers said.
Human antibodies have been a key treatment for serious COVID-19 cases during the pandemic, but typically need to be administered by infusion through a needle in the hospital, they said.
"Nanobodies have a number of advantages over human antibodies," said Professor Ray Owens, from Rosalind Franklin Institute and lead author of the research.
"They are cheaper to produce and can be delivered directly to the airways through a nebuliser or nasal spray, so can be self-administered at home rather than needing an injection," Owens said.
